Are you Dr. Zhou?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 8 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
33608 Ortega Hwy
San Juan Capistrano, CA 92675Phone+1 949-728-4188
Summary
- Dr. Weidong Zhou, MD is a board certified pathologist in San Juan Capistrano, California. She is currently licensed to practice medicine in California, Texas, and Colorado.
Education & Training
- University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 1997 - 2001
- Nanjing Medical UniversityClass of 1988
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- AZ State Medical License 2009 - 2026
- CA State Medical License 1998 - 2026
- FL State Medical License 2009 - 2026
- CO State Medical License 2010 - 2025
- KS State Medical License 2009 - 2025
- MI State Medical License 2009 - 2025
- OK State Medical License 2009 - 2025
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsInhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3Allison Bakovic, Nishank Bhalla, Farhang Alem, Catherine E. Campbell, Weidong Zhou
Viruses. 2021-08-03 - Use of magnetic nanotrap particles in capturing Yersinia pestis virulence factors, nucleic acids and bacteria.Alexandra N. Ii, Shih-Chao Lin, Benjamin Lepene, Weidong Zhou, Kylene Kehn-Hall
Journal of Nanobiotechnology. 2021-06-21 - 13 citationsProteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections.Michael D. Barrera, Victoria Callahan, Ivan V. Akhrymuk, Nishank Bhalla, Weidong Zhou
Pathogens. 2021-03-02
Press Mentions
- Characterization and Validation of Arg286 Residue of IL-1RAcP as a Potential Drug Target for OsteoarthritisFebruary 3rd, 2021